Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 4 » default
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (448)
- Volume 15, 2023 (56)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 4, 2012
Implications for breast cancer dormancy in other areas of medicine
Rameshwar P
Breast Cancer: Targets and Therapy 2012, 4:193-195
Published Date: 5 December 2012
Dormancy in breast cancer
Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H
Breast Cancer: Targets and Therapy 2012, 4:183-191
Published Date: 5 December 2012
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
Machado M, Einarson TR
Breast Cancer: Targets and Therapy 2012, 4:173-182
Published Date: 13 November 2012
Therapeutic reduction mammoplasty in large-breasted women with cancer using superior and superomedial pedicles
Denewer A, Shahatto F, Elnahas W, Farouk O, Roshdy S, Khater A, Hussein O, Teima S, Hafez M, Zidan S, Shams N, Kotb S
Breast Cancer: Targets and Therapy 2012, 4:167-172
Published Date: 25 October 2012
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory
Shah M, Allegrucci C
Breast Cancer: Targets and Therapy 2012, 4:155-166
Published Date: 26 October 2012
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy
Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, Smith SA, Miga MI, Abramson VG, Yankeelov TE
Breast Cancer: Targets and Therapy 2012, 4:139-154
Published Date: 11 October 2012
Potential of afatinib in the treatment of patients with HER2-positive breast cancer
Geuna E, Montemurro F, Aglietta M, Valabrega G
Breast Cancer: Targets and Therapy 2012, 4:131-137
Published Date: 27 August 2012
Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance
Yamamoto D, Tanaka K, Tsubota Y, Sueoka N, Shoji T, Kuwana K, Kwon AH
Breast Cancer: Targets and Therapy 2012, 4:125-129
Published Date: 27 August 2012
Sonomammographic characteristics of invasive lobular carcinoma
Kombar OR, Fahmy DM, Brown MV, Farouk O, El-Damshety O
Breast Cancer: Targets and Therapy 2012, 4:115-124
Published Date: 30 July 2012
Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing
Akter R, Hossain MZ, Kleve MG, Gealt MA
Breast Cancer: Targets and Therapy 2012, 4:103-113
Published Date: 13 July 2012
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
Bauer M, Bryce J, Hadji P
Breast Cancer: Targets and Therapy 2012, 4:91-101
Published Date: 20 June 2012
Targeting γ-secretase in breast cancer
Han J, Shen Q
Breast Cancer: Targets and Therapy 2012, 4:83-90
Published Date: 21 June 2012
Decreased risk of breast cancer associated with oral bisphosphonate therapy
Mathew A, Brufsky A
Breast Cancer: Targets and Therapy 2012, 4:75-81
Published Date: 23 May 2012
Role of pertuzumab in the treatment of HER2-positive breast cancer
Hubalek M, Brantner C, Marth C
Breast Cancer: Targets and Therapy 2012, 4:65-73
Published Date: 28 May 2012
New developments in the treatment of HER2-positive breast cancer
Nahta R
Breast Cancer: Targets and Therapy 2012, 4:53-64
Published Date: 7 May 2012
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Hurvitz SA, Kakkar R
Breast Cancer: Targets and Therapy 2012, 4:35-51
Published Date: 3 April 2012
Retraction
Singhai R
Breast Cancer: Targets and Therapy 2012, 4:33-34
Published Date: 8 March 2012
Psychiatric morbidity among Egyptian breast cancer patients and their partners and its impact on surgical decision-making
El-Hadidy MA, Elnahas W, Hegazy MAF, Hafez MT, Refky B, Abdel Wahab KM
Breast Cancer: Targets and Therapy 2012, 4:25-32
Published Date: 6 March 2012
A triple negative breast cancer: what it is not!
Katakkar SB
Breast Cancer: Targets and Therapy 2012, 4:21-23
Published Date: 24 February 2012
Potential clinical applications of halichondrins in breast cancer and other neoplasms
Ortega V, Cortes J
Breast Cancer: Targets and Therapy 2012, 4:9-19
Published Date: 8 February 2012
Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature
Kyrgias G, Theodorou K, Zygogianni A, Tsanadis K, Zervoudis S, Tzitzikas, Koukourakis M
Breast Cancer: Targets and Therapy 2012, 4:3-8
Published Date: 24 January 2012
Corrigendum
Menis J, Twelves C
Breast Cancer: Targets and Therapy 2012, 4:1-2
Published Date: 30 December 2011